You are here

Immatics

BMS’ Cost-Cutting Campaign Claims Collabs With Immatics, Century

BioSpace

Mon, 12/16/24 - 11:18 pm

Bristol Myers Squibb

Century Therapeutics

ESMO: Bristol Myers axes Immatics' bispecific after $150M bet

Fierce Biotech

Mon, 09/16/24 - 09:44 am

Bristol Myers Squibb

Moderna, Immatics agree to a cancer-focused collab that could top $1.7B

Medical Marketing and Media

Mon, 09/11/23 - 12:32 pm

Moderna Therapeutics

GSK's cell therapy retreat hits another partner as drugmaker exits Immatics collaboration

Endpoints

Thu, 11/17/22 - 10:38 am

BMS-backed Immatics' cell therapy shows early promise in small data set, prompting $110M offering

Fierce Biotech

Tue, 10/11/22 - 10:04 am

Bristol Myers Squibb

clinical trials

Immatics and Editas join up to bring CRISPR to 'gamma delta' cell therapy

BioPharma Dive

Tue, 06/7/22 - 10:22 am

Editas Medicine

gamma delta cell therapy

New Month, New Collaborations: BMS, Sorrento & Others Announce New Alliances

BioSpace

Fri, 06/3/22 - 09:14 am

Bristol Myers Squibb

Sorrento Therapeutics

prostate cancer

clinical trials

Caris Life Sciences

precision medicine

Bristol Myers triples-down on Immatics, bringing deal to $4.2B total biobucks

Fierce Biotech

Thu, 06/2/22 - 12:19 pm

Bristol Myers Squibb

Bristol Myers returns to Immatics for a dual-targeting cancer drug

BioPharma Dive

Tue, 12/14/21 - 11:10 am

Bristol Myers Squibb

Immatics' cell therapy blasts solid tumors in phase 1, but durability spooks investors. Will dialing up the dose help?

Fierce Biotech

Wed, 11/10/21 - 10:45 am

clinical trials

Immatics takes up the SPAC baton

EP Vantage

Wed, 03/17/21 - 11:27 pm

Immunocore IPO filing reveals kickback scheme, Immatics row and phishing attacks

Fierce Biotech

Tue, 01/26/21 - 11:32 am

Biotech GSK's cell therapy R&D lead jumps ship to partner Immatics

Fierce Biotech

Thu, 06/4/20 - 12:36 pm

A Covid-19 threat to business acquisitions

EP Vantage

Thu, 04/2/20 - 11:57 am

Gilead Sciences

GSK pays $50M for 2 solid tumor cell therapies from Immatics

Pharmaceutical Business Review

Thu, 02/20/20 - 10:23 am

Celgene Adds Cell Therapies From Immatics With Bristol Sale in Sight

Xconomy

Wed, 08/28/19 - 10:55 am

drug development

Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more

Endpoints

Thu, 07/12/18 - 06:27 pm

cancer immunotherapy

Amgen-partnered Immatics bags a $58M round to fund its first clinical steps on new T-cell tech for cancer

Endpoints

Wed, 10/4/17 - 11:23 am

Amgen, Immatics In Cancer Drug Partnership

Investopedia

Mon, 01/9/17 - 10:10 am

bispecific antibodies